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Abstract
Background: The most well known reproductive consequence of residence at high altitude (HA .2700 m) is reduction in
fetal growth. Reduced fetoplacental oxygenation is an underlying cause of pregnancy pathologies, including intrauterine
growth restriction and preeclampsia, which are more common at HA. Therefore, altitude is a natural experimental model to
study the etiology of pregnancy pathophysiologies. We have shown that the proximate cause of decreased fetal growth is
not reduced oxygen availability, delivery, or consumption. We therefore asked whether glucose, the primary substrate for
fetal growth, might be decreased and/or whether altered fetoplacental glucose metabolism might account for reduced fetal
growth at HA.
Methods: Doppler and ultrasound were used to measure maternal uterine and fetal umbilical blood flows in 69 and 58
residents of 400 vs 3600 m. Arterial and venous blood samples from mother and fetus were collected at elective cesarean
delivery and analyzed for glucose, lactate and insulin. Maternal delivery and fetal uptakes for oxygen and glucose were
calculated.
Principal Findings: The maternal arterial – venous glucose concentration difference was greater at HA. However, umbilical
venous and arterial glucose concentrations were markedly decreased, resulting in lower glucose delivery at 3600 m. Fetal
glucose consumption was reduced by .28%, but strongly correlated with glucose delivery, highlighting the relevance of
glucose concentration to fetal uptake. At altitude, fetal lactate levels were increased, insulin concentrations decreased, and
the expression of GLUT1 glucose transporter protein in the placental basal membrane was reduced.
Conclusion/Significance: Our results support that preferential anaerobic consumption of glucose by the placenta at high
altitude spares oxygen for fetal use, but limits glucose availability for fetal growth. Thus reduced fetal growth at high
altitude is associated with fetal hypoglycemia, hypoinsulinemia and a trend towards lactacidemia. Our data support that
placentally-mediated reduction in glucose transport is an initiating factor for reduced fetal growth under conditions of
chronic hypoxemia.
Citation: Zamudio S, Torricos T, Fik E, Oyala M, Echalar L, et al. (2010) Hypoglycemia and the Origin of Hypoxia-Induced Reduction in Human Fetal Growth. PLoS
ONE 5(1): e8551. doi:10.1371/journal.pone.0008551
Editor: Wen-Liang Zhou, Sun Yat-Sen University, China
Received August 18, 2009; Accepted December 3, 2009; Published January 1, 2010
Copyright:  2010 Zamudio et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors would like to acknowledge the support of the National Institutes of Health (HD042737, TW007444, SZ; HD046982, NI) and the National
Science Foundation (BCS-0309142, SZ) for the conduct of this research. The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Stacy.Zamudio@gmail.com
Introduction
Abnormalities of fetal growth cost billions per year in neonatal
intensive care, maternal hospital admissions and lost work
productivity for the worried parents. The subsequent financial
and social costs due to long-term damage to the fetus, e.g. physical
handicaps and/or diminished cognitive abilities, are inestimable
[1]. Intrauterine growth restriction (IUGR) affects 3–10% of
pregnancies with rates steadily increasing in the USA [2]; 20% of
stillborn infants have IUGR [3]. Perinatal mortality rates are 4–8
times higher for growth retarded infants, and morbidity is present
in 50% of surviving infants [3,4,5,6]. To date no intervention
other than delivery has proved effective. A common underlying
contributor to IUGR is placental hypoxia due to impaired
placental invasion of maternal blood vessels and/or poor placental
vascular development that diminishes the fetal vascular surface
area available for oxygen diffusion [7]. Determining the effects of
chronic hypoxia on human fetoplacental metabolism and growth
has long presented a challenge, due not only to ethical concerns
and problems of accessibility, but because hypoxia is almost always
present in combination with additional pathologies such as
abnormal placental development or preeclampsia. The natural
experiment afforded by human residence at high altitude allows us
to study fetal and placental responses to chronic hypoxia in the
absence of these additional pathologies. This report describes fetal
glucose delivery and consumption in low and high altitude
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there is no fetal oxygen deficit at high altitude and thus that
hypoxia is not the proximate cause of the reduction in fetal
growth.
Pregnancy at .2700 m altitude is associated with reduced third
trimester fetal growth; these babies do not attain their genetic
growth potential during intrauterine life [8]. Previous studies in
diffusion-dependent avian models demonstrate that it is the high-
altitude environment, specifically reduced oxygen tension [9] that
ultimately causes the reduction in fetal growth, as growth
restriction is reversible with supplemental oxygen. Other models,
where the placenta can profoundly modulate gas and nutrient
delivery to the fetus, show variable degrees of growth restriction at
high altitude depending on the species, timing of exposure etc. In
the sheep model, for example, maternal and fetal hematological
adaptations defend fetal oxygen supply and permit normalization
of fetal growth [10,11]. This is not the case in humans. Altitude
diminishes birth weight by 100 grams per 1000 m gain in
elevation [12], and the effect is independent of maternal attributes
and socioeconomic characteristics [9,13].
We have shown that placental and fetal hypoxia are present in
human high-altitude pregnancy [14,15,16]. However, the reduced
growth of an otherwise healthy fetus in the third trimester is not
due to a reduced quantity of oxygen delivered to or consumed by
the fetus [8,17]. Although the idea that deficit in maternal oxygen
transport is the causal mechanism for reduced fetal growth has
been promoted by one group [18,19], numerous experimental
animal studies show that maternal blood flow to the uteroplacental
unit can be reduced by up to 50% without reduction in fetal
growth [reviewed in 20]. We recently published the first studies of
maternal and fetal oxygen delivery and consumption in genetically
matched women at low versus high altitude. We found that
maternal oxygen delivery to the uteroplacental unit is 5-fold
greater than fetal consumption and that fetal oxygen delivery and
consumption is the same at low versus high altitude [8,17]. We
found that, as in the sheep model, the human fetus vigorously
defends its oxygen supply. Thus despite an approximately 40%
reduction in maternal arterial oxygen tension, umbilical venous
oxygen tension was reduced by only 10% [10], within one
standard deviation of normal sea level values [21]. These data
point to alterations in placental function and/or metabolism as
both defending fetal oxygenation while at the same time reducing
fetal growth.
In view of the reduction in fetal weight at high altitude, the
absence of changes in fetal oxygen delivery and consumption
raises a crucial question. What is the mechanism for the reduction
in fetal growth? After oxygen, glucose is the most important
substrate for fetal growth, and the only one that can be
metabolized anaerobically. We hypothesized that the reduction
in fetal growth in conditions of chronic hypoxia is associated with
decreased delivery of glucose to the fetus and decreased fetal
glucose consumption. We hypothesized also that the decrease in
fetal glucose delivery was a result of increased anaerobic
metabolism of glucose by the placenta.
Materials and Methods
Ethics Statement
All participants gave written, informed consent to protocols
approved by the collaborating Bolivian institution (Instituto
Boliviano de Biologı ´a de Altura, Consejo Tecnico), the Bolivian
National Bioethics Committee and the Institutional Review Board
of the New Jersey Medical School.
Study Design/Participants
The study reported here is part of a larger, cross-sectional,
prospective study designed to evaluate the effect of altitude on
uterine arterial and umbilical blood flows, oxygen delivery and
consumption and on fetal and placental growth in adapted (Native
American) versus non-adapted (European Hispanic) populations
living at low and high altitude in Bolivia [8,17]. The blood flow,
oxygen delivery and oxygen consumption data have been
published for the full sample, and showed that while blood flow
and oxygen delivery were greater in Andean women, regardless of
altitude, changes attributable to altitude were the same between
ancestry groups [8,17].
The participants included in this report are 69 mother-infant
pairs living at 400 m altitude (Santa Cruz, Bolivia) and 58 at
3600 m (La Paz, Bolivia), the subset in whom maternal and fetal
arterial and venous plasma samples were successfully collected and
measured for glucose, lactate and insulin. In this report we present
the relevant data on blood flows, oxygen delivery and consump-
tion for this subset.
Inclusion criteria were singleton pregnancy, good health
(absence of obstetric or medical complications including chronic
conditions such as hypertension, renal disease, obesity), a normal
oral glucose tolerance test, conception, gestation and delivery at
the altitude of study and elective cesarean delivery without labor at
term. Women were excluded if labor began prior to cesarean
delivery, for drug, alcohol or tobacco use, or if they developed
complications of pregnancy.
Study Protocol
Prior to delivery (461days, range, 0–10), we obtained a
medical/obstetric history, evaluated general measures of health
(blood pressure, oxygen saturation, urinalysis) and completed a
research ultrasound that measured bilateral maternal uterine
blood flow and fetal umbilical venous blood flow in fasting women
as previously published [8,17,22]. Maternal ‘‘arterialized’’
(warmed hand vein) and venous blood was obtained prior to
delivery for measurement of blood gases, glucose, lactate, insulin
and for determinations of hematocrit and hemoglobin, required
for calculation of oxygen content and delivery. Using ‘arterialized’
maternal venous blood, obtained after warming the hand vein, is a
widely practiced technique for obtaining mixed venous and
arterial blood that largely reflects arterial blood values, especially
for metabolites [23,24]. It is frequently used where it is impossible,
impractical or clinically and/or ethically unacceptable to sample
arterial blood directly. It has been used frequently in pregnancy to
obtain values for maternal arterial blood gases (see for example
[25]). At delivery the doubly-clamped cord and placenta were
immediately sampled for blood from the umbilical vein and artery
and for tissue samples from the villous core. Samples for blood gas
analyses were collected into heparinized blood gas syringes which
were sealed and immediately placed on ice. Blood gases were
measured within 1 hour of collection. Samples for glucose and
lactate were collected into tubes containing calcium oxalate and
into lithium heparin for insulin determinations. Plasma for these
latter three assays was separated immediately, then frozen at
280uC until assay. The acceptance criteria for the venous and
arterial/arterialized samples was that oxygen was not administered
to the mother prior to blood collection or clamping of the
umbilical cord, that arterial pH differed from venous by .0.02,
and that arterial PCO2 was $3.8 mmHg higher than venous
PCO2 [21]. This ensured that cord blood samples were not
inadvertently collected from the same vessel, or from mixed
venous and arterial cord blood. Blood gases were measured in
duplicate using a Radiometer ABL 5000 (Copenhagen, Denmark)
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low altitude; the machines were calibrated prior to every study
using the manufacturers’ standard calibration solutions. The CV
of duplicate measures did not exceed 2% for any blood gas or
hematological parameters. Hemoglobin was measured using a
Radiometer OSM 3 (Copenhagen, Denmark) calibrated daily
using the manufacturers standards, or by the cyanomethemoglo-
bin technique.
Placental weight was measured after trimming the cord and
membranes. Ponderal index, which estimates neonatal body mass,
was calculated as 100 * birth weight (g)/birth length (cm)
3. All
subjects in this study were delivered under spinal or epidural
anesthesia without supplemental oxygen. Placental tissue samples
were obtained and syncytiotrophoblast basal plasma membranes
were prepared as described previously [26] for analysis of the
GLUT1 glucose transporter, the only functional glucose trans-
porter at the maternal-fetal interface.
The ultrasound methods for measurement of volumetric blood
flow have been described in detail in our prior publications
[8,17,22]. Briefly, we used ultrasound and Doppler to measure the
diameter and blood mean flow velocity in the left and right
maternal uterine arteries and in the fetal umbilical vein to
calculate volumetric blood flow to the pregnant uterus and to the
fetus [27,28]. These techniques have been validated in prior
studies using measurements obtained directly by flow probe [29].
Volumetric flow (ml.min
21) was calculated as the cross-sectional
area of the blood vessel x mean flow velocity x 60. Blood flows and
oxygen delivery were summed for the left and right uterine arteries
within each participant and are presented as bilateral flow and
oxygen delivery.
Plasma glucose concentrations were measured using a hexoki-
nase-glucose-6-phosphate dehydrogenase coupled enzyme assay
[30]. Plasma lactate was determined using a lactate dehydrogenase
enzymatic assay [31]. Plasma insulin concentration was measured
by a commercial ELISA (Diagnostic Systems Laboratories,
Webster, TX), according to the manufacturer’s instructions. In
each assay a pooled sample from all subjects was run in triplicate
to measure inter-assay variation. Intra-assay variation in triplicate
samples was 361% for glucose, 261% for lactate and 561% for
insulin. Inter-assay variation was 462% for glucose, 361% for
lactate and 862% for insulin. The mean (or median) differences
observed between groups in these parameters were substantially
greater than the variations due to assay errors. GLUT1 glucose
transporter expression was measured in the syncytial basal
membrane by slot immunoblotting using a polyclonal antibody
to GLUT1 (Chemicon, Temecula, CA) as described previously
[15].
Maternal glucose delivery to the uteroplacental unit was
calculated as maternal bilateral uterine blood flow multiplied by
arterial glucose concentration and normalized to uterine contents
(birth weight plus placental weight) in units of mmol.min
21.kg
21.
Fetal glucose delivery was calculated as umbilical venous blood
flow multiplied by umbilical venous concentration of glucose
(mmol.min
21). Fetal glucose consumption was calculated as the
umbilical venous-arterial difference in glucose concentration





Because the parent project involved comparisons of blood flow
and oxygen delivery between four groups, Andean Native
Americans versus Hispanics of European ancestry living at high
versus low altitude [8,17], our initial statistical analyses were
conducted to ascertain whether or not any of the dependent
variables in this study of glucose transport and consumption
differed according to ancestry. For only one of the dependent
variables, umbilical arterial lactate, was there interaction between
altitude and ancestry; the altitude-associated increase in lactate
was greater in the Hispanic than Andean women. Therefore the
ancestry groups were combined to increase statistical power and
the data reported here are based on altitude differences only. Our
prior studies showed that while blood flow and oxygen delivery
were greater in Andean women, regardless of altitude, changes
attributable to altitude were the same between ancestry groups.
Although the ancestry groups were combined to obtain the data
reported in this study, the ancestry-specific data at each altitude is
reported in supplementary data tables for the interested reader
(Tables S1-S3).
At each altitude, most of the continuous data presented in this
report were sampled from a population which approximated a
Gaussian distribution as indicated by the p value derived from the
Kolmogorov-Smirnoff statistic (p.0.1) except for GLUT1 glucose
transporter expression and insulin concentrations. Within each
group maternal age, height, pre-pregnant BMI, weight gain with
pregnancy, parity, infant sex, and gestational age at birth were
analyzed using multiple regression to evaluate the impact of
maternal and fetal characteristics on birth weight. Birth weights
were then adjusted for significant contributors to fetal weight
(maternal age, parity, infant sex and gestational age). The
difference in the male/female distribution between altitudes was
analyzed by Fishers Exact test. Glucose and lactate concentrations
were compared between altitudes using a two-tailed, unpaired
Student’s t test. The Mann-Whitney U test was used to compare
GLUT1 glucose transporter expression and the plasma insulin
values. Because the initial statistical analyses compared 4 groups, a
Bonferroni correction was applied to the altitude comparisons
reported here and the p value accepted for significance was ,0.01.
Correlation analyses were used to evaluate relationships between
independent and dependent continuous variables. Normally
distributed data in figures and tables are presented as mean 6
SEM; insulin and glucose transporter and insulin data are
presented as medians and inter-quartile range.
Results
Ethnicity and Altitude
Of the demographic and neonatal characteristics considered in
relation to birth weight, maternal age, BMI, height, weight gain,
parity and infant sex explained 26% of the variation in birth weight
among Europeans at high altitude (p=0.15), 18% in Andean at low
altitude (p=0.24) and 24% in Andean at high altitude (p=0.15).
Taller European women at high altitude had larger babies
(r
2=0.12, p,0.05) and males were heavier than females
(r
2=0.07, p=0.11), regardless of altitude. Greater BMI in Andean
women at low altitude contributed to greater birth weight (r
2=0.12,
p,0.05) and greater parity among Andean women at high altitude
was associated with greater birth weight (r
2=0.12 p,.05). We
therefore adjusted the individual birth weights within each group,
controlling for these variables and for gestational age (Table S1).
Controlling for differences in maternal and neonatal characteristics
between groups, the altitude-associated decrement in birth weight
was 2442 grams for Europeans and 2237 grams for Andeans.
Apart from neonatal anthropometry, only one of the dependent
variables presented in this paper, umbilical arterial lactate, showed
interaction between altitude and ancestry; the altitude-associated
increase in lactate was greater in the European than Andean
women. Therefore the ancestry groups were combined to increase
statistical power and the data reported here reflect altitude
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reported in supplementary data tables for the interested reader
(Tables S2, S3).
Maternal and Neonatal Characteristics
High altitude mothers were older (461y r s ; p ,0.0001) and
shorter (461 cm; p=0.02) than their low-altitude counterparts, but
comparable in all other respects (Table 1). The altitude-associated
decrement in birth weight was 326 grams. The growth restriction
was asymmetric as birth length and body weight were reduced but
head circumference was similar at 400 versus 3600 m. Placental
weight was similar, but the birth to placental weight ratio was
reduced, thus the placenta was larger for any given fetal weight at
3600 m (Table1). The unequaldistribution ofsexes betweenthe low
and high altitude populations should be noted, however it is not
statistically significant. Table 1 indicates that the adjusted birth
weights between altitudes, corrected for this uneven distribution,
were only minimally different from the raw birth weights.
Blood Flows
Pregnant women at high altitude had reduced bilateral uterine
artery volumetric blood flow (Table 2). However, increases in
maternal hemoglobin concentration raised maternal arterial
oxygen content at 3600 m (6.860.1 vs. 7.960.1 mmol.L
21 at
400 m and 3600 m, respectively, p,0.001) and this compensated
for reduced blood flow so that uteroplacental O2 delivery was
similar between altitudes (Table 2). Fetal umbilical venous blood
flow was also reduced at high altitude. However, as in the
mothers, an increase in fetal oxygen content (4.560.1 at 400 m
vs. 5.560.2 mmol.L
21 at 3600 m, p,0.01), among other
adaptations previously reported [17], preserved oxygen delivery
and consumption to comparable values between altitudes
(Table 2).
Maternal Glucose
Maternal arterial glucose concentrations were similar at low
versus high altitude (Fig. 1A). Maternal venous glucose concen-
Table 1. Maternal and infant characteristics.
Maternal characteristics 400 m 3600 m p values
n=69 n=58
Gestational age at ultrasound 38.060.2 38.060.2 =0.84
Age (years) 28613 2 61* ,0.0001
Parity (#), (% primiparous) 1.260.2 (39%) 1.260.10 (32%) =0.87, 0.78
Height (cm) 159611 5 5 61 =0.02
Non-pregnant weight (kg) 61615 9 61 =0.50
Non-pregnant Body Mass Index (kg.m
22)2 4 612 5 61 =0.51
Weight gain with pregnancy (kg) 12611 3 61 =0.38
Infant characteristics
Birth weight (grams, (unadjusted values) 3479649 3180653 * ,0.0001
Birth weight (grams, adjusted values) 3485623 3159638 * ,0.0001
Placental weight (g) 465611 498615 =0.07
Birth/placental weight ratio 7.760.2 6.660.2 * ,0.0001
Ponderal index 2.6960.03 2.7860.04 =0.09
Birth length (cm) 50.560.2 48.660.2 * ,0.001
Abdominal circumference (cm) 34.160.2 33.760.2 =0.21
Head circumference 34.760.2 34. 560.2 =0.38
Clinically assessed gestational age at birth (wks) 38.660.1 38.660.1 =0.62
Days (from LMP) 272612 7 1 61 =0.36
Sex ratio M/F 34/35 24/34 =0.37
doi:10.1371/journal.pone.0008551.t001
Table 2. Blood flows, oxygen delivery and consumption.
400 m 3600 m p values
n=69 n=58
Bilateral maternal uterine blood flow (ml.min
21.kg
21 uterine contents [fetal + placental weight]) 17269 13668 ,0.005
Uteroplacental O2 delivery (mmol.min
21.kg
21 uterine contents) 1.260.1 1.160.1 =0.36
Fetal blood flow (ml.min
21.kg
21 fetal weight) 100648 0 63 ,0.0001
Fetal oxygen delivery (mmol.min
21.kg
21 fetal weight) 0.4460.02 0.4460.02 =0.93
Fetal oxygen consumption (mmol.min
21.kg
21 fetal weight) 0.2760.01 0.2760.01 =0.97
doi:10.1371/journal.pone.0008551.t002
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arterial to venous (MA-MV) difference in glucose was therefore
greater at high altitude (Fig. 1B), suggesting that the high altitude
mothers were extracting more glucose from the arterial to venous
circulation than the low altitude mothers. Despite the reduction in
uterine blood flow (Table 2), maternal glucose delivery to the
uteroplacental circulation was similar at low versus high altitude
(Fig. 1C). Maternal arterial and venous glucose concentrations
were positively correlated (r
2=0.36, p,0.001, low altitude;
r
2=0.24, p,0.005, high altitude).
Fetal Glucose
Glucose concentrations in both the umbilical vein and artery
were decreased at high altitude (Fig. 2A). The magnitude of the
decrease between the umbilical venous and arterial circulations
was similar, thus the fetal venous to arterial difference (FV-FA) in
glucose concentration did not differ between altitudes (Fig. 2B).
Also notable is the fact that the maternal arterial-fetal arterial
(MA-FA) glucose gradient at high altitude is much greater than
that observed at low altitude (2.1160. 15 mM vs. 1.5160.10 mM,
p,0.001). Umbilical venous and arterial glucose concentrations
were positively correlated (r
2=0.65, p,0.001, low altitude;
r
2=0.43, p,0.001, high altitude). Glucose extraction by the fetus
is equivalent to glucose consumption, as there is no gluconeogen-
Figure 1. Maternal glucose concentrations and uterine glucose
delivery. (A) Maternal arterial and venous plasma glucose concentra-
tions in normal, term pregnancies at low vs. high altitude. Arterial
glucose concentrations were similar at low (4.360.1 mM) and high
altitude (4.560.1 mM, p=0.06), but venous concentrations were
reduced at high altitude (3.560.1 at 400 m and 3.260.1 at 3600 m,
p,0.005). (B) Maternal arterial-to-venous differences in plasma glucose
concentration were lower at 400 m (0.8560.1 mM) than at 3600 m
(1.4060.1 mM, p,0.0001). (C) Maternal uterine glucose delivery was
similar at 400 m (0.7360.04 mmol.min
21.kg
21 uterine contents) and
3600 m (0.6360.04 mmol.min
21.kg
21 uterine contents, p=0.06).
doi:10.1371/journal.pone.0008551.g001
Figure 2. Fetal glucose concentrations and fetal glucose
consumption. (A) Umbilical venous and arterial plasma glucose
concentrations in normal, term pregnancies at 400 and 3600 m.
Glucose concentrations were greater in the umbilical vein at 400 m
(3.560.1 mM) than at 3600 m (2.960.1 mM, p,0.0001). Fetal umbilical
arterial glucose concentrations were also greater at low (2.860.1 mM)
than at high altitude (2.860.1 vs. 2.360.1 mM, p,0.0001). (B) Fetal
venous-to-arterial differences in plasma glucose concentration were
similar at 400 m (0.7460.06 mM) and 3600 m (0.6260.06 mM),
p=0.16). (C) Fetal glucose consumption at was greater at 400 m than
3600 m.
doi:10.1371/journal.pone.0008551.g002
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volumetric blood flows we can calculate fetal glucose consumption.
Using the FV-FA differences in glucose concentration and the
associated fetal blood flows (Table 2), we found that chronic
hypoxia caused a decrease in fetal glucose consumption from
68.765.8 to 49.566.6 mmol.min
21.kg
21 (Fig. 2C; p,0.01).
Neither birth nor placental weights were associated with
maternal or fetal glucose concentrations, nor with the consump-
tion of glucose at either altitude. There was no relationship
between oxygen and glucose consumption at either altitude. When
we examined glucose consumption relative to oxygen consumption
(glucose:oxygen quotient) we found that the high altitude fetus was
consuming less glucose per mole of oxygen at high versus low
altitude (Fig. 3A). Fetal glucose delivery was positively associated
with fetal glucose consumption at both altitudes but the slope of
the relationship was 2-fold greater in high compared to low
altitude pregnancies (Fig. 3B).
Metabolic Responses
To determine whether these changes in fetal glucose concen-
trations/consumption affected fetal metabolic response, we
measured the lactate concentrations in the umbilical vein and
artery (Fig. 4A). Umbilical venous lactate was similar between
altitudes, whilst umbilical arterial lactate concentration was
increased at high altitude. As a result of the wide range of plasma
lactate values, net lactate fluxes were not significantly different
from zero at either low or high altitude. Umbilical arterial lactate
concentration was negatively correlated with umbilical arterial O2
content, but the slopes and intercepts were similar between
altitudes (y=4.5 2 1.2(x)+0.2(x
2), r
2=0.24, p,0.005 at 400 m;
y=4.9 2 1.0(x)+0.15(x
2), r
2=0.20, p,0.005) at 3600 m).
Figure 3. Indicators of fetal glucose metabolism. (A) The fetal
glucose/oxygen quotient (6 x fetal glucose consumption/fetal oxygen
consumption) was greater at 400 m (1.6460.13) than at 3600 m
(1.1860.13 p,0.01). (B) Fetal glucose delivery and fetal glucose
consumption were positively correlated both altitudes (y=0.08+0.176x,
r




Figure 4. Fetal lactate and insulin response to altered glucose
delivery and consumption. (A) Umbilical venous plasma lactate
concentrations in normal, term pregnancies at 400 vs 3600 m did not
differ (3.3660.09 mM at 400 m and 3.6760.13 mM at 3600 m, p=0.06),
whilst arterial concentrations were lower at 400 m (3.2260.11 mM) than
at 3600 m (3.8060.17, p,0.005). (B) Insulin concentrations were greater
in the low vs. high altitude fetus (low altitude, median =84.7 pmol.ml
21
[54.1–170.1]; high altitude, median =53.5 pmol.ml
21 [38.2–79.2]). (C)
Fetal glucose and insulin concentrations were positively correlated at
both altitudes (400 m y =265.2+52.4x r
2=0.34, p,0.0001; 3600 m y =
249.4+40.5x, r
2=0.33, p,0.0001) but neither the slopes (p=0.42) nor
intercept (p=0.11) differed.
doi:10.1371/journal.pone.0008551.g004
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changes in glucose delivery and consumption, we measured
umbilical venous plasma insulin concentrations. Insulin concen-
trations were decreased in high versus low altitude neonates
(Fig. 4B). Umbilical venous glucose and insulin concentrations
were positively correlated (Fig. 4C), but neither the slopes nor
intercept differed at low vs. high altitude, suggesting that fetal
insulin response to glucose was similar at low and high altitude.
Glucose Transporters
Previously, in a smaller sample with a reduced altitude
difference (1600 vs 3100 m), we showed that expression of the
GLUT1 glucose transporter on the basal membrane of the
syncytiotrophoblast was reduced by ,40% [15]. We repeated
these measurements by immunoblotting of the isolated placental
syncytiotrophoblast basal membranes from a randomly chosen
subset of the pregnancies described in Table 1. Expression of
GLUT1 decreased from a median value of 1.91 [1.03–6.03] at low
altitude, to 1.03 [0.68–2.14] at high altitude (arbitrary units;
p,0.01; n=30, 32).
Discussion
The birth weight of neonates at 3600 m is reduced .300 g
compared to low altitude pregnancies, despite the fact that
maternal and fetal oxygen delivery and fetal oxygen consumption
do not differ between altitudes. Maternal glucose delivery to the
placenta did not differ between altitudes but both umbilical venous
and arterial glucose concentrations were significantly decreased at
high altitude. This was associated with a .28% reduction in fetal
glucose consumption, a 37% decrease in median fetal plasma
insulin concentrations and a trend towards fetal lactacidemia at
high altitude. The hypothesis that reduced fetal weight was
associated with decreased fetal glucose delivery and consumption
was supported. The hypothesis that increased metabolism of
glucose by the placenta contributes to the reduction in glucose
consumption was supported by the observation of decreased
delivery of glucose to the high altitude fetus despite a greater
maternal arterial to fetal arterial gradient. Finally, the hypothesis
that there might be increased anaerobic metabolism of glucose by
the placenta at high altitude was supported by decreased delivery
of glucose in the absence of changes in oxygen delivery to placenta
and fetus. The amount of glucose delivered to the fetus was
strongly associated with the amount of glucose consumed,
presumably contributing to the growth (or lack thereof) of the
fetus. The relationship between glucose delivery and consumption
was far more pronounced at high altitude, suggesting that glucose
dependency in the high altitude fetus may be increased relative to
the low-altitude fetus. In contrast, the amount of insulin secreted
relative to fetal glucose concentrations did not differ between
altitudes, indicating that decreased fetal growth is not attributable
to alterations in the fetal insulin response. These results lead us to
conclude that the reduction in fetal growth due to chronic hypoxia
is mediated not by limitations on oxygen availability, but by fetal
hypoglycemia and its consequences. The model of high altitude
pregnancy reveals that an initiating step in IUGR may be
decreased glucose delivery to the fetus, presumably as a result of
the increased placental consumption of the glucose delivered by
the mother to the uteroplacental circulation.
As is often the case in human studies our ability to definitively
prove the hypotheses above is limited by ethical and access
concerns. Ideally, samples from the uterine vein would have
permitted a direct calculation of total uteroplacental glucose and
oxygen uptake allowing a direct partition between uteroplacental
and fetal glucose and oxygen uptake. Such samples are rarely
acquired in humans, even in the most sophisticated of medical
settings and were not ethically permissible nor feasible under the
conditions extant in Bolivia. Likewise blood flow measurements
are known to be variable. We took great care to measure our
pregnant women as close to elective cesarean delivery as possible,
in the same position and at the same time of day; replicate
measures and our coefficients of variation were similar to those
previously published [34,35,36]. The un-normalized bilateral
uterine blood flow measurement reported here of 670632 vs.
505630 ml.min
21 at low and high altitude respectively are
entirely consistent with the several prior studies using multiple
methodologies that converge on a mean value of ,700 ml.min
21
(reviewed in [37]). It is reassuring that the fetal blood flow
measurements reported in Table 2 fell, on average, at the 75
th
percentile (400 m) and the 60
th percentile (3600 m) relative to a
large, population based analysis of serially studied pregnancies
[34] and that our oxygen consumption measurements were
virtually identically to the only other human data, recently
published [38].
Our data showed that maternal arterial glucose concentrations
were marginally greater, but venous concentrations were markedly
reduced at high altitude, suggesting greater MA-MV extraction of
glucose at 3600 m. We have no measures in the non-pregnant
state so this could be a generalized attribute of high altitude
residence. However, the only other report on plasma glucose
showed that the MA-MV difference in the non-pregnant condition
was equivalent at sea level and 4300 m altitude, but increased
progressively with gestational age [39]. This supports the
possibility that increased placental extraction and consumption
of glucose accounts for the increased MA-MV difference. In a
prior study, maternal plasma insulin was lower in high compared
with low altitude pregnancy [40], indicating that the reduced
maternal venous glucose concentration is not a function of an
insulin-stimulated increase in glucose uptake in pregnancy. This
supports that the cause of the increased MA-MV difference in
glucose concentration during pregnancy at high altitude is
increased glucose extraction by the uteroplacental circulation.
The umbilical FV-FA difference in glucose concentration we
report here is similar to those obtained in prior studies
[32,41,42,43,44]. Previous studies on the association between fetal
glycemic status and fetal growth have clearly shown that reduced
fetal blood glucose concentrations are associated with fetal growth
restriction [44,45,46,47], but these measurements were obtained
after the clinical diagnosis of IUGR was made. In our model this
difference in fetal metabolic state is present at the time that growth
is slowed, but prior to reaching a pathological threshold. In
addition, measurement of the corresponding umbilical flows have
allowed us to determine, for the first time in humans, fetal glucose
consumption. This is also the first direct demonstration that
reduced fetal growth is associated with decreased fetal glucose
consumption. We show a strong relationship between fetal glucose
delivery and consumption, such that greater glucose delivery
increases fetal glucose consumption. This causal pathway,
coupling fetal hypoglycemia to fetal growth restriction is supported
in animal models [48,49,50,51] and there is indirect evidence to
demonstrate this relationship in human studies [52,53,54].
Complementary to the glucose data is the altitude-associated
decrease in fetal plasma insulin, a factor noted consistently in
conditions of fetal growth restriction [46,47,55]. We have shown
that greater fetal glucose concentrations are associated with
greater fetal insulin secretion, again highlighting the importance
of glucose in moderating fetal growth at any altitude. The
conditions of maintained placental weight, fetal oxygenation and
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fetal growth as being initiated by relative hypoglycemia and
hypoinsulinemia. It is worth noting that while our 3600 m
umbilical venous plasma glucose samples fell at ,20
th percentile
for gestational age [44], none were below the threshold for clinical
neonatal hypoglycemia, defined as the 5
th centile value (1.55 mM)
for plasma glucose in neonates 1–2 hr after birth [56].
Despite the increased maternal extraction of glucose at high
altitude and similar rates of glucose delivery to the placenta
between altitudes, glucose transfer across the placenta at high
altitude was only 60% of that measured at low altitude. This
implicates the placenta as the source of alterations that lead to the
reduced maternal-fetal transfer of glucose. One possible source of
the reduced glucose transfer is the decrease in syncytial basal
membrane glucose transporter expression, since previous data has
suggested that transport across the basal membrane is the rate-
limiting step in transplacental glucose transport [57]. We believe
that the reduction in basal membrane glucose transporter
expression is a secondary effect and not causally related to
decreased maternal-fetal glucose transfer, since the effect of
hypoxia on trophoblast cells is to increase, not decrease, glucose
transporter expression [58,59].
There are two other possible causes for decreased transfer of
glucose into the fetal circulation. The first is decreased delivery to
the placenta by the maternal circulation as a result of decreased
uterine blood flow and the second is increased placental
metabolism of glucose which reduces the level of glucose available
for transfer to the fetal circulation. With respect to the former, our
previous in vitro studies have shown that a decrease in intervillous
blood flow consistent with the magnitude of reduction in uterine
arterial blood flow at high altitude would only reduce fetal glucose
transfer by ,12% [60]. This would be an overestimation as
intervillous blood flow is only a fraction of uterine blood flow.
Moreover it should be noted that the maternal arterial-fetal
arterial glucose gradient we report at high altitude is much greater
than that at low altitude (2.11 vs. 1.51 mM). Since this is a
significant factor promoting maternal-fetal transfer [61,62] and it
runs counter to the small decrease likely to result from reduced
uterine delivery, it is implausible that the decrease in uterine
delivery is responsible for the markedly decreased concentrations
in the fetus. The alternative is an increased placental metabolism
of glucose, reducing the amount of glucose available for transfer to
the fetal circulation. Contrary to previous findings comparing the
glucose/oxygen quotient in normal and growth-restricted preg-
nancies [41], the increased maternal arterial-fetal arterial glucose
concentration difference at high altitude is associated with a
decreased glucose/oxygen quotient. This means that despite
conditions which should promote increased placental transfer,
fetal glucose delivery and consumption are decreased, pointing to
increased glucose consumption by the placenta as the cause of
decreased transport to the fetus. Support for this concept can be
drawn from the increased umbilical arterial lactate concentration
seen at high altitude. While the net lactate flux data ostensibly
demonstrates a switch from fetal consumption at low altitude to
fetal production at high altitude, the wide range of plasma lactate
values means that neither flux is significantly different from zero.
Interestingly however, the inverse correlation between umbilical
arterial lactate and O2 content reflects the same relationship
observed by Marconi et al in IUGR pregnancies [63].
The large change in glucose delivery to the fetus is in marked
contrast to fetal oxygen delivery, which is not different between
altitudes despite a substantial decrease in maternal arterial oxygen
tension from ,12 kPa to 7 kPa [8,17]. We suspect that the
increased consumption of glucose is accompanied by decreased
placental consumption of oxygen, which would explain the relative
preservation of a normal fetal oxygen tension and fetal oxygen
consumption at 3600 m. These observations are reminiscent of a
mechanism known as metabolic reprogramming, in which
hypoxia-driven, active inhibition of oxidative metabolism is
combined with increased anaerobic use of glucose [64,65] to
produce a hypometabolic state that is reversed when oxygen
tension rises. In the models thus far described this mechanism
results in increased cellular oxygen availability, enhancing the
survival of tumor cells and sparing oxygen to permit increased
growth [64] or inducing hypoxia-tolerance in muscle [66,67]. In
the placenta metabolic reprogramming is likely to play a unique
and important role in the regulation of fetal growth. The
maintenance of fetal oxygenation and the decreased placental
transfer of glucose at high altitude are consistent with the
operation of such a mechanism in the placenta. Increased
availability of oxygen and decreased availability of glucose occur
as a result of alterations in placental metabolism, producing a
change in the substrate mix provided to the fetus. While increased
oxygen availability enhances fetal survival, decreased glucose
availability leads to a reduction in fetal growth.
The mechanism described above may be a crucial first step in
the processes collectively known as the developmental origins of
health and disease [68], whereby an abnormal uterine condition
such as hypoxemia results in (semi) permanent changes in adult
metabolic and cardiovascular function. In view of the decreased
fetal plasma insulin levels observed in the high altitude fetus, it is
worth noting the decrease in pancreatic b cell mass and function
which accompany hypoglycemia-associated fetal growth restric-
tion in fetal sheep [69,70,71]. If b cell dysfunction is associated
with hypoglycemia/hypoinsulinemia-mediated reductions in hu-
man fetal growth as suggested by these observations, the effect of
placentally-mediated alterations in the substrate mix delivered to
the fetus s may be carried through to adulthood with the attendant
consequences for adult health.
In conclusion, we have shown that chronic (altitude-induced)
hypoxia results in decreased fetal circulating glucose concentra-
tions and reduced fetal glucose consumption. Occurring under
conditions where oxygenation is sufficient to maintain fetal
oxidative metabolism, these data support that hypoglycemia-
mediated fetal growth restriction is a result of alterations in
placental metabolism.
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